The primary market is gearing up for a stellar week as three companies are set to launch their initial public offerings (IPOs) to raise over Rs 2,700 crore.

The primary market saw major listings in both the mainboard and small- and medium-sized enterprise (SME) segments in June, keeping investors engaged with subscriptions and listings. Moving into July, the first week is abuzz with activity, featuring new listings and initial public offerings (IPOs) available for subscription.

India’s strong macroeconomic environment and promising growth prospects provide an ideal backdrop for the vibrant IPO market. Analysts expect significant capital deployment in public markets and strong demand for both new-age and conventional companies in the near term.

In the coming week, the IPOs of Emcure Pharmaceuticals, where Shark Tank fame Namita Thapar serves as Executive Director, and Bansal Wire will open for subscription in the mainboard segment. Additionally, Ambey Laboratories will be the sole SME issue.

Here are the IPOs which will open for subscription this week –

Emcure Pharma IPO

Pune-based Emcure Pharmaceuticals is set to launch its maiden public issue for subscription on July 3, closing on July 5. The company has fixed a price band of Rs 960 to Rs 1,008 per share for its Rs 1,952-crore IPO.

The issue consists of a mix of fresh equity shares worth Rs 800 crore and an offer-for-sale (OFS) of 1.14 crore equity shares by existing shareholders, including promoters. The anchor book of the issue will be launched for a day prior to the public subscription.

Bansal Wire Industries IPO

The initial public offering (IPO) of Bansal Wire is set to open for subscription on July 3 and will close on July 5. The company has set a price band of Rs 243-256 per share. At the upper end of this price band, Bansal Wire aims to raise approximately Rs 745 crore. 

Investors can bid for a minimum of 58 shares in one lot and in multiples thereafter. The public offer is being conducted through the book-building process, with around 50% of the issue reserved for qualified institutional buyers, 35% for retail investors, and 15% for non-institutional investors.

Ambey Laboratories IPO

The SME IPO of Ambey Laboratories is set to open for subscription on July 4, 2024, and will close on July 8, 2024. The IPO is a book-built issue totaling Rs 44.68 crore. 

It consists of a fresh issuance of 62.58 lakh shares, aggregating to Rs 42.55 crore, and an offer-for-sale (OFS) of 3.12 lakh shares, aggregating to Rs 2.12 crore.

New Listings this week –

Allied Blenders and Distillers IPO

Shares of the mainboard IPO are set to debut on stock exchanges BSE and NSE on July 2, 2024. Refunds will be initiated on July 1, with shares being credited to demat accounts on the same day.

Vraj Iron and Steel Limited

Shares of the Vraj Iron and Steel Limited are set to debut on stock exchanges BSE and NSE on July 3, 2024. Refunds will be initiated on July 2, with shares being credited to demat accounts on the same day.

Shivalic Power Control:

The shares of Shivalic Power Control will debut on July 1, 2024.

Sylvan Plyboard (India)

The shares of Sylvan Plyboard will debut on July 1, 2024.

Mason Infratech: 

The shares of Mason Infratech will debut on July 1, 2024.

Visaman Global Sales: 

The shares of Visama Global will debut on July 1, 2024.

Akiko Global Services: 

Shares will debut on July 2, 2024, with allotment finalized on July 1. Refunds will be initiated, and shares will be credited to demat accounts on the same day.

Petro Carbon and Chemicals: 

Shares will debut on July 2. Refunds will be initiated on July 1, and shares will be credited to demat accounts the same day.

Diensten Tech: 

Shares will debut on July 3. The allotment will be finalized on July 2. Refunds will be initiated on July 1, and shares will be credited to demat accounts the same day.

Nephro Care India: 

Shares will debut on July 5. The allotment will be finalized on July 3. Refunds will be initiated on July 4, and shares will be credited to demat accounts the same day.

(Disclaimer: Views, recommendations, and opinions expressed are personal and do not reflect the official position or policy of Financial Express.com. Readers are advised to consult qualified financial advisors before making any investment decisions. Reproducing this content without permission is prohibited.)